Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SCI Foundation, formerly known as the Schistosomiasis Control Initiative (SCI), is a non-profit global health organization focused on the elimination of parasitic worm infections. Based in London, the organization partners with governments in sub-Saharan Africa to implement and scale up mass drug administration (MDA) programs targeting schistosomiasis and soil-transmitted helminthiasis. SCI Foundation provides essential technical assistance, logistical support, and monitoring and evaluation services to ensure the effective delivery of preventative chemotherapy. The organization is recognized for its evidence-based approach and has consistently been ranked as a top-rated charity by GiveWell for its high impact and cost-effectiveness. By facilitating the distribution of medicines like praziquantel and albendazole, SCI Foundation aims to improve health outcomes and economic productivity in affected communities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Schistosomiasis Control Initiative.